Lurbinectedin is a medication used to treat small cell lung cancer (SCLC) and has been granted orphan drug status by the FDA [1]. According to sources [2] and [3], a Phase 3 clinical trial is currently underway to investigate the effectiveness of lurbinectedin in combination with atezolizumab, an immunotherapy drug, for the treatment of extensive-stage SCLC. The trial is expected to enroll approximately 600 participants and will take place at multiple locations across the United States, Europe, and Asia. The study's primary endpoint is progression-free survival, with secondary endpoints including overall survival and objective response rate. More information on this trial can be found on the Jazz Pharmaceuticals website [3]. In summary, a Phase 3 clinical trial investigating the use of lurbinectedin in combination with atezolizumab for the treatment of extensive-stage SCLC is currently underway.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.targetedonc.com/view/phase-3-investigation-of-lurbinectedin-plus-atezolizumab-underway-in-es-sclc
[3] https://www.jazzpharma.com/science/clinical-trials/